Evidence map›Paper›PMID 29706655›Full record

ArticleOncogene2018

Novel tumour suppressive protein encoded by circular RNA, circ-SHPRH, in glioblastomas.

S Begum, A Yiu, J Stebbing, L Castellano

Abstract read
PubMed Publisher
In one paragraph

Article in Oncogene, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 70 papers.

0numbers the graph read from it
0cells of the map it votes in
70citing papers in PubMed
5.7field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

70 citing papers in PubMed, 100 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Coding circular RNA in human cancer.Genes & diseases · 2025
    Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Circular RNA vaccine in disease prevention and treatment.Signal transduction and targeted therapy · 2023
    Review
  14. Review
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Review

10 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

S BegumDivision of Computational and Systems Medicine, Department of Surgery and Cancer, Faculty of Medicine, Imperial College London, South Kensington Campus Exhibition Road, London, SW7 2AZ, UK.
A YiuDivision of Cancer, Department of Surgery and Cancer, Faculty of Medicine, Imperial College London, Hammersmith Campus Du Cane Road, London, W12 0NN, UK.
J StebbingDivision of Cancer, Department of Surgery and Cancer, Faculty of Medicine, Imperial College London, Hammersmith Campus Du Cane Road, London, W12 0NN, UK.
L CastellanoDivision of Cancer, Department of Surgery and Cancer, Faculty of Medicine, Imperial College London, Hammersmith Campus Du Cane Road, London, W12 0NN, UK. l.castellano@imperial.ac.uk.ORCID http://orcid.org/0000-0002-3059-4829
Imperial College London · GBUniversity of Sussex · GB

Funding

Department of Health NIHR-RP-011-053
6 · The paper itself

Abstract

The previously unchartered gene expression territory governed by circular RNAs is becoming clearer with the onset of deeper sequencing technologies. The translation of circular RNAs remained a controversial theory until earlier this year, when two studies [1, 2] showed endogenous circular RNA translation in vitro and in vivo, and have further provided mechanistical evidence. In this edition of Oncogene, Zhang et al., provide evidence for the first circular RNA translated with relevance to cancer; a novel tumour suppressor protein, SHPRH-146aa, produced by circ-SHPRH driven by IRES elements. The novel tumour suppressor protein produced by the circular RNA was found to work in synergy with the full-length protein, behaving as a protective decoy molecule to decrease degradation, and thus increasing the tumour suppressive functionality of the gene. An extended patient survival time was seen in glioblastoma patients with elevated levels of SHPRH-146aa. This study also marks the discovery of the first circular RNA with an overlapping initiation and termination codon, resulting in the translation of the full circRNA, exploring a mechanism not previously found or seen.

Indexed as

Codon, TerminatorDNA HelicasesGlioblastomaHumansRNARNA, CircularTumor Suppressor ProteinsUbiquitin-Protein LigasesCodon, TerminatorDNA HelicasesRNARNA, CircularSHPRH protein, humanTumor Suppressor ProteinsUbiquitin-Protein Ligases

Identifiers

PMID29706655
OpenAlexW2800157923

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.